Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia

Summary

Thrombopoietin receptor agonists (TPO-RA) have recently been introduced for the treatment of immune thrombocytopenia (ITP), an antiplatelet-antibodies autoimmune disease. The observation of a low frequency of bleeding episodes despite their thrombocytopenia suggests the existence of a compensatory mechanism. This study aimed to evaluate the effect of TPO-RA treatment on platelet function and on the procoagulant state in ITP patients before (ITP-bR) and after responding (ITP-aR) to treatment. Plasma- and microparticle (MP)-associated procoagulant capacity from ITP patients was similar before and after responding to the TPO-RA regimen but higher than the healthy control values. High MP-associated procoagulant activity did not seem to be due to increased platelet activation, since platelet stimulation by agonists was reduced in ITP-bR and ITP-aR patients. It could be related to increased platelet apoptosis, evaluated in terms of surface phosphatidylserine (PS), observed in both ITP groups. In summary, TPO-RA treatment increased platelet count but did not ameliorate their function and did not change plasma- and MP-associated procoagulant state of ITP patient responders to this therapy.

Keywords

Thrombopoietin receptor agonists - platelets - thrombin generation - microparticle-associated procoagulant state

• References

• 1 Cuker A, Cines DB. Immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2010; 2010: 377-384.
• 2 Stasi R, Newland AC. ITP: a historical perspective. Br J Haematol 2011; 153: 437-450.
• 3 Neunert C, Lim W, Crowther M. et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-4207.
• 4 Panzer S, Hocker L, Rieger M. et al. Agonist-inducible platelet activation in chronic idiopathic autoimmune thrombocytopenia. Eur J Haematol 2007; 79: 198-204.
• 5 Provan D, Stasi R, Newland AC. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-186.
• 6 Cuker A. Toxicities of the thrombopoietic growth factors. Semin Hematol 2010; 47: 289-298.
• 7 Kim KJ, Baek IW, Yoon CH. et al. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies. Br J Haematol 2013; 161: 706-714.
• 8 Norgaard M. Thrombosis in patients with primary chronic immune thrombocytopenia. Thromb Res 2012; 130 (Suppl. 01) S74-75.
• 9 Sewify EM, Sayed D, Abdel Aal RF. et al. Increased circulating red cell microparticles (RMP) and platelet microparticles (PMP) in immune thrombocytopenic purpura. Thromb Res 2013; 131: e59-63.
• 10 Schipperus M, Fijnheer R. New therapeutic options for immune thrombocy-topenia. Neth J Med 2011; 69: 480-485.
• 11 Rodeghiero F, Stasi R, Gernsheimer T. et al. Standardisation of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386-2393.
• 12 Hayashi S, Oshida M, Kiyoi T. et al. Reticulated platelet determination: methodologies and applications for the evaluation of thrombocytopenic disorders. Rinsho Ketsueki 1999; 40: 205-212.
• 13 Hemker HC, Giesen PL, Ramjee M. et al. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83: 589-591.
• 14 Harker LA. Platelets in thrombotic disorders: quantitative and qualitative platelet disorders predisposing to arterial thrombosis. Semin Hematol 1998; 35: 241-252.
• 15 Harker LA, Marzec UM, Hunt P. et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88: 511-521.
• 16 Peng J, Friese P, Wolf RF. et al. Relative reactivity of platelets from thrombopoietin- and interleukin-6-treated dogs. Blood 1996; 87: 4158-4163.
• 17 Psaila B, Bussel JB, Linden MD. et al. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood 2012; 119: 4066-4072.
• 18 Martin M, de Paz R, Jimenez-Yuste V. et al. Platelet apoptosis and agonist-mediated activation in myelodysplastic syndromes. Thromb Haemost 2013; 109: 909-919.
• 19 Ghanima W, Lee SY, Barsam S. et al. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. Br J Haematol 2012; 158: 811-814.
• 20 Dielis AW, Castoldi E, Spronk HM. et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008; 06: 125-131.
• 21 Lacroix R, Dignat-George F. Microparticles as a circulating source of procoagulant and fibrinolytic activities in the circulation. Thromb Res 2012; 129 (Suppl. 02) S27-29.
• 22 Bouchard BA, Gissel MT, Whelihan MF. et al. Platelets do not express the oxidized or reduced forms of tissue factor. Biochim Biophys Acta. 2013 Epub ahead of print.
• 23 Bouchard BA, Mann KG, Butenas S. No evidence for tissue factor on platelets. Blood 2010; 116: 854-855.
• 24 Jy W, Johansen ME, Bidot Jr C. et al. Red cell-derived microparticles (RMP) as haemostatic agent. Thromb Haemost 2013; 110: 751-760.
• 25 Schoenwaelder SM, Jarman KE, Gardiner EE. et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011; 118: 1663-1674.
• 26 Kuter DJ, Rummel M, Boccia R. et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363: 1889-1899.
• 27 Sarpatwari A, Bennett D, Logie JW. et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010; 95: 1167-1175.
• 28 Bussel JB, Kuter DJ, Pullarkat V. et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113: 2161-2171.
• 29 Cheng G, Saleh MN, Marcher C. et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377: 393-402.